Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.
Psychedelic: atai Life Sciences reports BPL-003 study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...
Atai Life Sciences announces results from BPL-003 Phase 2a open-label study
Life Sciences (ATAI) announced topline results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in 12 patients with moderate to ...
BPL-003 shows promise in alcohol use disorder study
NEW YORK and BERLIN - atai Life Sciences (NASDAQ: ATAI), a biopharmaceutical company focused on mental health treatments with a current market capitalization of $243 million, announced positive ...
Enid News & Eagle10d
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 ...
A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three ...
BioSpace9d
Atai Touts Positive Data for Psychedelic Therapy in Alcohol Use Disorder
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...